BeOne Medicines Ltd. SEC Filings

BeOne Medicines Ltd. (ONC) reported a profitable Q3. Total revenues were $1,412,284 for the three months ended September 30, 2025, driven by product revenue of $1,395,013. Net income was $124,841, a clear turnaround from a loss a year ago, as gross profit rose to $1,215,774 and operating income reached $163,114.

Cash generation was strong with year‑to‑date operating cash flow of $710,233, lifting cash and cash equivalents to $4,036,868. The company monetized future IMDELLTRA royalties, receiving $885,000 upfront from Royalty Pharma, recorded as a royalty sale liability with a 6.4% effective annual rate. BRUKINSA led product sales at $1,040,691 in the quarter, followed by TEVIMBRA at $190,623. Short‑term debt stood at $813,296 and long‑term debt at $139,571. Shares outstanding were 1,438,553,263 as of November 1, 2025.

BeOne Medicines Ltd. (ONC) filed an 8-K announcing its third-quarter 2025 results. The company reported that it announced financial results for the three months ended September 30, 2025, and furnished a related press release as Exhibit 99.1 titled “BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates.”

The information provided under Item 2.02 is being furnished and is not deemed “filed” under the Exchange Act. The filing also lists the company’s securities, including American Depositary Shares trading on Nasdaq under ONC, with each ADS representing 13 ordinary shares; the ordinary shares are listed on the Stock Exchange of Hong Kong under 06160.

John Oyler, Chief Executive Officer and Director of BeOne Medicines Ltd. (ONC), reported sales of American Depositary Shares on 09/16/2025 under a Rule 10b5-1 trading plan adopted on March 12, 2025. The Form 4 lists six sale transactions totaling 28,203 ADS at weighted-average prices ranging approximately from $323.61 to $327.78 (footnotes provide per-transaction ranges). Each ADS represents 13 ordinary shares. The filing shows multiple pools of ordinary shares held directly or indirectly through trusts and entities, with the reporting person disclaiming beneficial ownership of certain holdings. The form is signed by an attorney-in-fact on behalf of the reporting person.

BeOne Medicines Ltd. (ONC) director Wang Xiaodong reported a change in beneficial ownership on a Form 4 covering transactions dated 09/09/2025. The filing shows 148,096 ordinary shares were disposed of under transaction code G, reported at a price of $0, and described in the footnotes as bona fide gifts exempt from Section 16(b). After the reported transaction, the Form 4 lists 5,006,674 ordinary shares as directly beneficially owned and additional indirect holdings of 1,025,063, 3,953,100, and 50 shares held through family and trust entities, with the reporting person disclaiming beneficial ownership for certain trust-held positions. The form was signed by an attorney-in-fact on 09/11/2025.

BeOne Medicines insider sale and holdings summary. The reporting person, Global Head of R&D, disclosed a sale of 5,000 American Depositary Shares (ADS) executed under a Rule 10b5-1 trading plan at a weighted average price of $350.0623 per ADS. The report shows 1,023,529 ordinary shares previously reported as disposed and an indirect beneficial ownership position of 601,965 ordinary shares held through Wang Holdings LLC. The filer also disclosed a contribution of RMB10 million to an employee participation plan that purchased RMB-denominated shares in the issuer's STAR Market offering; the filer disclaims voting and dispositive power over those RMB Shares.

BeOne Medicines Ltd. (ONC) Form 144 notice reports a proposed sale of 9,010 ADS (American Depositary Shares) through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $3,163,681.30 and approximately 54,564,278 ADS outstanding. The filing shows the securities were mainly acquired via an exercise of stock options on 09/10/2025 (8,894 ADS, paid in cash) and restricted stock units on 06/15/2025 (116 ADS). The filer disclosed prior sales in the past three months: 9,342 ADS (10b5-1 sale) on 08/13/2025 for $2,805,905.17, 920 ADS on 07/30/2025 for $280,232.74, and 422 ADS on 06/16/2025 for $112,463.00. The notice includes the usual representation about absence of undisclosed material adverse information and reference to Rule 10b5-1 trading plans where applicable.

BeOne Medicines director Corazon D. Sanders reported multiple transactions on 09/05/2025. The filing shows a disposal of 57,226 Ordinary Shares, an acquisition and a subsequent disposition of 2,665 American Depositary Shares (ADS) on the same date with reported prices of $155.68 (acquisition) and $337 (disposition). The report also discloses a grant of a share option covering 34,645 ordinary shares with an exercise price of $11.98, exercisable under specified vesting conditions and expiring on 06/21/2032. Each ADS represents 13 ordinary shares. The form is signed by an attorney-in-fact on behalf of the reporting person on 09/09/2025.

BeOne Medicines Ltd. (ONC) Form 144 notice: The filer notified a proposed sale of 5,000 ADS through Morgan Stanley Smith Barney at an aggregate market value of $1,732,250.00, with an approximate sale date of 09/09/2025 on NASDAQ. The securities were acquired on 05/17/2022 by previously exercised stock options and paid in cash. The filing also discloses recent sales by the related parties: 7,675 ADS were sold during the past three months in multiple transactions generating gross proceeds of $2,210,354.28. The filer affirms no undisclosed material adverse information and, where applicable, reliance on a trading plan or instructions is noted in the form.

BeOne Medicines Ltd. (ONC) filing a Form 144 reports a proposed sale of 2,665 common shares with an aggregate market value of $898,105.00. The securities were acquired and are planned to be sold on 09/05/2025 following an exercise of options under a registered plan, with cash payment recorded on that date. The broker listed for the proposed sale is Morgan Stanley Smith Barney LLC, Executive Financial Services, New York and the sale is expected to occur on NASDAQ. The filer states there were no securities sold in the past three months by the selling person and includes the standard representation that the seller does not possess undisclosed material adverse information about the issuer.